Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00494026
Status:
TERMINATED
Last Update Posted:
2009-11-20
First Post:
2007-06-27
Brief Title:
Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer SCLC
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Phase II Study of Concurrent Carboplatin Pemetrexed and Radiotherapy for Limited Stage of Small Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study stopped early based on interim results of another trial showing inferior activity of pemetrexedcarboplatin compared to etoposidecarboplatin in SCLC
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter phase II open-label trial to evaluate the efficacy of pemetrexed carboplatin combined with thoracic radiotherapy in patients with Limited Stage of small cell lung cancer
Detailed Description:
Two 21-day cycles of pemetrexed 500 milligrams per square meter mgm2 intravenous IV infusion and carboplatin target area under the curve AUC 5 IV infusion followed by two 21-day cycles of pemetrexed 500 mgm2 IV infusion and carboplatin target AUC 5 IV infusion with concurrent radiotherapy 2 Gray Gy per fraction 5 fractions per week up to a dose of 50 Gy is administered
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-MC-S095 | None | None | None |